RP Scherer Technologies has synthesized new antibody-drug conjugates (ADCs) comprising camptothecine or camptothecine derivatives linked to a polypeptide such as an antibody through a linker reported to be useful for the treatment of cancer.
Vellore Institute of Technology University (VIT) and BG Negev Technologies and Applications have described new curcumin or piperine analogues acting as NF-kappaB (NFKB) activation inhibitors and/or quorum sensing signaling inhibitors reported to be useful for treatment of cancer, fungal and bacterial infections and inflammatory disorders.
Beckley Psytech has divulged ergoline analogues acting as 5-HT2A and/or 5-HT2B and/or 5-HT2C receptor agonists reported to be useful for the treatment of depression.
Chengdu Baiyu Pharmaceutical has presented pyrimidine derivatives acting as GTPase KRAS (Gly12Cys mutant) inhibitors reported to be useful for the treatment of cancer.
Monte Rosa Therapeutics has synthesized new proteolysis targeting chimera (PROTAC) compounds comprising a protein cereblon (CRBN) binding moiety covalently linked to a eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1)-targeting moiety reported to be useful for the treatment of cancer.
The National Institute of Pharmaceutical R&D (Beijing) has described bridged heterocyclyl-substituted pyrimidine compounds acting as tyrosine-protein kinase JAK-1 and/or non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of inflammation, autoimmune disease and cancer.
GlaxoSmithKline has divulged mas-related G protein-coupled receptor member X2 (MRGPRX2) antagonists reported to be useful for the treatment of osteoarthritis, migraine, asthma, irritable bowel syndrome, atopic dermatitis, psoriasis, urticaria and rheumatoid arthritis, among other disorders.
Anticancer Bioscience and the J Michael Bishop Institute of Cancer Research have described fused azepine compounds reported to be useful for the treatment of cancer.
The National Institute of Pharmaceutical R&D (Beijing) has identified condensed heterocyclic compounds acting as insulin secretagogues and gluconeogenesis inhibitors reported to be useful for the treatment of diabetes.
RSS